To Flavor or Not to Flavor Extemporaneous Omeprazole Liquid
Author(s): Chuong Monica C, Taglieri Catherine A, Kerr Stephen G
Issue: Nov/Dec 2017 - Volume 21, Number 6
View All Articles in Issue
Page(s): 500-512
Download in electronic PDF format for $75
Abstract: Omeprazole is a proton pump inhibitor used to treat the symptoms of gastro esophageal reflux disease, ulcers, excess stomach acid, infection with Helicobacter pylori, and to control the gastric side effects of various drugs. The approved dosage forms in the U.S. are powder in compounding kits, delayed-release granules for oral suspension, oral delayed-release tablets, and oral delayed-release capsules. An extemporaneously compounded unsweetened oral liquid method, published in the International Journal of Pharmaceutical Compounding, was found to be commonly used by pharmacists. This project investigated the robustness of the compendium omeprazole high-performance liquid chromatographic assay in evaluating an oral liquid made from commercial delayed-release pellets, the potency of extemporaneously compounded solutions having a 1.125% v/v flavored versus unflavored samples stored at controlled cold temperatures at different time points, and examining the absorption spectrum of the flavoring agent. As part of the study, stability-indication testing was also conducted. The studies indicate that the chromatographic area under the plasma concentration-time curve of both study groups remained over 90% of the label claim during the follow-up period. The flavor did not significantly impact the pH of the oral liquid. This study further identified (1) an increase in resilient foam formation in the flavored liquid, potentially hindering dosing accuracy, (2) omeprazole is oxidized easily by 3% hydrogen peroxide, and (3) flavoring agent absorbs in an ultraviolet visible spectroscopy spectral range often used in assay detectors for quantification of drug molecules, and could interfere with assay protocols of the same.
Related Keywords:
Monica C. Chuong, PhD, Catherine A. Taglieri, PharmD, Stephen G. Kerr, PhD, omeprazole, proton pump inhibitors, PPIs, gastroesophageal reflux disease, GERD, Helicobacter pylori, gastric ulcers, stomach acid, gastric side effects, oral liquid preparation, foam formation, flavoring agents, stability
Related Categories:
EXCIPIENTS, GASTROENTEROLOGY, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, DOSAGE FORMS/DRUG CARRIERS
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
To Flavor or Not to Flavor Extemporaneous Omeprazole Liquid
Chuong Monica C, Taglieri Catherine A, Kerr Stephen G
|
Nov/Dec 2017
Pg. 500-512
|
Compatibility of Flavoring Agents in Compounding Extemporaneous Omeprazole Oral Liquid
Chuong Monica, Taglieri Catherine A, Huang Szu Yu, Sariol Anthony, Kitigawa Reina, Barman Koushik, Mistry Amee, Harris Donna L, Kerr Stephen G
|
Nov/Dec 2019
Pg. 504-510
|
Featured Excipient: Flavor Enhancing Agents
Allen Loyd V Jr
|
Jan/Feb 2003
Pg. 48-50
|
Proton Pump Inhibitor Homogenous Suspensions: A Compounding Solution to Pediatric Gastroesophageal Reflux Disease
Corsini Lindsay, Williams LaVonn A
|
Mar/Apr 2011
Pg. 124-128
|
Omeprazole 1 mg/mL and 4 mg/mL in Humco Flavor Sweet Sugar-Free Oral Liquid
Allen Loyd V Jr
|
Jan/Feb 2019
Pg. 58
|
Flavors and Flavoring
Allen Loyd V Jr
|
Mar/Apr 1997
Pg. 90-92
|
Stability of Omeprazole Extemporaneous Oral Solution in Chopin Base
Spennacchio Antonio, Lopedota Angela Assunta, la Forgia Flavia Maria, Fontana Sergio, Denora Nunzio, Lopalco Antonio
|
May/Jun 2023
Pg. 250-255
|
Omeprazole 2-mg/mL Oral Liquid
Allen Loyd V Jr
|
Sep/Oct 2006
Pg. 389
|
The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment
Meissner Svenja, Bansal Mahima, Dela Cruz Paula Donamae, Hanning Sara, Svirskis Darren
|
Mar/Apr 2020
Pg. 140-147
|
Compounded Levofloxacin Triple Therapy is Safe and Effective for Refractory Helicobacter pylori
Mah Xian-Jun, Gupta Vikas, Loch Srey Neth, Ahlenstiel Golo, van de Poorten David
|
Jul/Aug 2017
Pg. 330-333
|
Stability of Omeprazole in SyrSpend SF Alka (Reconstituted)
Whaley Paul A, Voudrie Mark A II, Sorenson Bridget
|
Mar/Apr 2012
Pg. 164-166
|
Omeprazole 2 mg/mL in SyrSpend SF Alka (Reconstituted)
Allen Loyd V Jr
|
Sep/Oct 2019
Pg. 409
|
Flavoring: Compounding a Treat
Kloesel Lawson G
|
Jan/Feb 2001
Pg. 13-16
|
Case Report: Wound Care of a Diabetic Foot Ulcer
Wynn Tom
|
Jul/Aug 2004
Pg. 265-267
|
Pantoprazole Sodium 2-mg/mL Oral Liquid
Allen Loyd V Jr
|
Sep/Oct 2006
Pg. 391
|
Long-term Stability of Esomeprazole in 5% Dextrose Infusion Polyolefin Bags at 5°C ± 3°C after Microwave Freeze-thaw Treatment
Hecq Jean-Daniel, Rolin Catherine, Godet Marie, Gillet Patricia, Jamart Jacques, Galanti Laurence M
|
Nov/Dec 2015
Pg. 521-524
|
Ranitidine Hydrochloride 15-mg/mL Oral Liquid
Allen Loyd V Jr
|
Mar/Apr 2007
Pg. 161
|
Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
|
Jul/Aug 2003
Pg. 288-291
|
The Treatment of Canine Atopic Disease
Davidson Gigi S
|
May/Jun 2002
Pg. 210-215
|
Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh
Allen Loyd V Jr
|
Nov/Dec 2003
Pg. 449-450
|
Return to Top |